August 7th, 2011
Ablating short-segment Barrett esophagus: What’s your weapon of choice?
The first cases of Barrett esophagus (BE) ablation in the late 1980s used YAG and Argon laser. Since then, a myriad of ablation techniques have been described, including multipolar electrocautery (MPEC), argon plasma coagulation (APC), cryotherapy, radiofrequency ablation (RFA), and endoscopic mucosal resection (EMR). Each technique has had its advocates, and some of the techniques appear to have certain advantages in certain types of BE: e.g., long segment, nodular, etc.
Most cases of BE are short segment, and most neoplastic cases do not have nodules or erosions. So the question I would like to see discussed is: In a patient with 1–2 cm of otherwise featureless flat but neoplastic BE:
What ablation technique would you use, and what do you feel makes this technique advantageous?
What would be your second option, and when would you employ it?
Do you use more than one technique, and, if so, which ones do you use and why?
What are the most common complications you see with BE ablation?
What is your overall success at complete BE elimination?
We look forward to your comments.
Categories: Patient care
Tags: Barrett esophagus
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

M. Brian Fennerty, MD
Founding Editor
NEJM Journal Watch Gastroenterology
Learn more about Gut Check on Gastroenterology.
Search the Archive
Archives by Date
From NEJM: Recently in Gastroenterology- CORE Principles in the Management of Severe Hypertriglyceridemia January 29, 2026Management of hypertriglyceridemia for reducing the risk of serious clinical complications, including hypertriglyceridemia-induced acute pancreatitis, has historically been formidable and frustrating for clinicians and patients. Challenges are related to variable success in adherence to the lifestyle modifications that are required to reduce triglyceride levels, the predominantly polygenic and multifactorial determinants...
- Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk January 29, 2026In two phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo.
- A New Therapeutic Broadcast on Hepatitis D, a Satellite Virus January 22, 2026Hepatitis D virus (HDV) is known as a satellite virus because it requires the hepatitis B virus (HBV) surface antigen (HBsAg) to enter the hepatocytes and to complete its life cycle. HDV is the smallest human pathogen, with a single-stranded RNA genome that is approximately 1.7 kb long. Yet, chronic...
- Reusable versus Single-Use Duodenoscopes January 22, 2026This feature about the use of duodenoscopes offers a case vignette accompanied by two essays, one supporting availability of single-use duodenoscopes and the other recommending reusable duodenoscopes.
- A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D January 22, 2026Tobevibart plus elebsiran and tobevibart alone both lowered HDV RNA and ALT levels. The combination resulted in a high incidence of undetectable HDV RNA and an HBsAg level below 10 IU/ml at week 48.
- CORE Principles in the Management of Severe Hypertriglyceridemia January 29, 2026
-
Tag Cloud
- Ambulatory endoscopy center antiretroviral therapy Barrett esophagus boceprevir bowel preparation CMS colitis colonoscopy colorectal cancer screening CT colonography DDW drug interactions efavirenz endoscopist Endoscopy gastroenterology GI bleeding hepatitis HIV IBS Irritable Bowel Syndrome Medicare midazolam nurse Plavix PPIs primary care probiotics ritonavir Screening colonoscopy sedation sigmoidoscopy telaprevir training virtual colonoscopy
